Bipartisan Senate Letter Urges FDA to Schedule All Kratom, Not Just 7-OH
Senators Ricketts and Blumenthal led a bipartisan letter urging FDA Commissioner Makary to pursue scheduling for the whole kratom leaf, arguing that targeting only 7-OH would leave addictive products on shelves. Meanwhile, at least 12 states have banned 7-OH outright, Texas AG Paxton sued two retailers, and a Medical College of Wisconsin study reported a 6,500 percent increase in kratom exposures over 13 years.
A bipartisan group of 12 senators is pressing the FDA to schedule the entire kratom plant under the Controlled Substances Act, calling the agency's focus on concentrated 7-hydroxymitragynine (7-OH) alone a loophole. The letter, which surfaced publicly this week, puts senators at odds with both the FDA's own July 2025 recommendation and President Trump's recent remarks about approving "natural 7-OH." Separately, state-level enforcement continues to accelerate, and a new study documents a 6,500 percent rise in kratom-related poison center reports over 13 years.
Senate letter calls 7-OH-only scheduling a loophole
In March 2026, Sen. Pete Ricketts (R-NE) and Sen. Richard Blumenthal (D-CT) sent a letter to FDA Commissioner Marty Makary urging the agency to recommend scheduling for the whole kratom leaf, according to a press release from Ricketts' office. The letter argued that scheduling only concentrated 7-OH would leave kratom products containing the alkaloid at natural levels on retail shelves, tacitly declaring them safe for consumption.
The letter drew co-signatures from ten additional senators: Marsha Blackburn (R-TN), John Boozman (R-AR), Katie Britt (R-AL), Ted Budd (R-NC), Mike Crapo (R-ID), Steve Daines (R-MT), Jim Justice (R-WV), Alex Padilla (D-CA), and Jeanne Shaheen (D-NH). The bipartisan composition is notable. Three Democrats and nine Republicans signed, suggesting the push for broader scheduling crosses party lines.
The letter's framing directly conflicts with two other positions in play at the federal level. The FDA's July 2025 recommendation to the Drug Enforcement Administration (DEA) targeted synthetic and concentrated 7-OH preparations, leaving natural kratom leaf outside the scheduling recommendation. And President Trump's May 11 statement, in which he said his administration was "looking seriously" at approving "natural 7-OH," drew a distinction between natural and synthetic forms that the senators' letter rejects.
The result is three competing federal signals: an FDA recommendation to schedule concentrated 7-OH, a presidential statement suggesting natural forms could be approved, and a Senate letter arguing the entire plant should be scheduled. The DEA, which has not acted on the FDA's eight-month-old recommendation, has not indicated which direction it is leaning.
State 7-OH bans reach 12, enforcement actions multiply
While federal action stalls, states have moved ahead. According to ABC6, at least 12 states have enacted full bans on 7-OH: Alabama, Arkansas, California, Florida, Indiana, Kentucky, Louisiana, Mississippi, Rhode Island, Tennessee, Vermont, and Wisconsin. Five additional states (Arizona, Colorado, South Carolina, Texas, and West Virginia) have implemented restrictions targeting high-potency formulations rather than outright bans.
Enforcement is also intensifying. On April 21, Texas Attorney General Ken Paxton sued two California-based kratom retailers, Pure Leaf Kratom and Outcast Distribution, for selling products that Paxton's office said contained 86 to 96 percent 7-OH. Texas law caps 7-OH concentration at two percent. The products at issue contained the alkaloid at nearly 50 times that limit, according to the attorney general's filing. KERA reported additional details on the enforcement action, noting that both companies are based in California and were selling into Texas through online channels.
In Missouri, Attorney General Hanaway's investigation has expanded to 22 firms across the kratom supply chain, spanning manufacturers, distributors, and retailers.
The state-level pattern is consistent with what Ohio regulators are considering: states are acting on concentrated 7-OH products without waiting for the DEA. The patchwork of bans, concentration caps, and enforcement actions creates a fragmented compliance landscape for companies operating across state lines.
Study: kratom poison center reports rose 6,500 percent in 13 years
A study published April 29 in the journal Addiction by researchers at the Medical College of Wisconsin (MCW) found that kratom exposures reported to U.S. poison centers increased from 19 in 2010 to 1,242 in 2023, a 6,500 percent increase over the study period.
Severe outcomes tracked a similar trajectory. The MCW researchers reported zero severe outcomes in 2010 and 158 in 2023. The study also found that states with kratom bans had lower rates of both exposure reports and severe outcomes compared to states with less regulation, according to Medscape's coverage of the paper.
The figures reflect poison center call volume, which captures a specific slice of kratom-related incidents rather than total use. Poison center data tends to over-represent acute adverse events and under-represent routine use without incident. The study's authors noted the limitations but argued the trend line warranted regulatory attention.
The findings arrive as the industry debates how to distinguish between natural kratom leaf and concentrated 7-OH products in both messaging and regulation. The MCW study did not break out exposures by product type (leaf, extract, or concentrated 7-OH), a gap that limits its usefulness for the natural-versus-synthetic distinction that dominates the current policy debate.
Sources
-
Ricketts Letter Calls on FDA to Address Kratom Scheduling Loophole
Office of Sen. Pete Ricketts
Ricketts and Blumenthal led a bipartisan letter urging FDA Commissioner Makary to pursue scheduling for all kratom, not only concentrated 7-OH.
-
Growing Crackdown: More States Ban Synthetic Kratom or 7-OH Before Federal Government
ABC6
At least 12 states have enacted full bans on 7-OH, with additional states implementing restrictions on high-potency formulations.
-
Attorney General Paxton Sues Kratom Retailers Selling Products Containing Nearly Fifty Times Legal Limit
Texas Attorney General
Paxton sued Pure Leaf Kratom and Outcast Distribution for selling products containing 86-96% 7-OH, nearly 50 times the 2% limit under Texas law.
-
Ken Paxton Kratom Texas Attorney General California
KERA
Background on Paxton's enforcement action against two California-based kratom retailers operating in Texas.
-
Kratom Use Is Surging in the US with Life-Changing Consequences
Medical College of Wisconsin Newsroom
Kratom exposures reported to poison centers increased from 19 in 2010 to 1,242 in 2023, a 6,500% increase.
-
US Kratom Use Surges 65-Fold in 13 Years
Medscape
Coverage of the Medical College of Wisconsin study on rising kratom exposures and severe outcomes reported to US poison centers.